Tafinlar (dabrafenib) 75 mg hard capsules, 120 capsules — generic (Bangladesh) Targeted cancer therapy. Drug delivery from Europe within 4-5 days, guaranteed storage conditions, payment upon receipt. Order by calling +380996042415, Viber, or WhatsApp.

Indications

As monotherapy, dabrafenib is indicated for the treatment of unresectable or metastatic melanoma with a BRAF V600e mutation, as detected by an FDA-approved test.

In combination with trametinib, dabrafenib is indicated for the treatment of:

unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.

adjuvant treatment of melanoma with BRAF V600E or V600K mutations and node-positive disease after complete resection.

treatment of metastatic BRAF-mutated non-small cell lung cancer (NSCLC) V600E.

Treatment of locally advanced or metastatic anaplastic thyroid cancer (ATC) with the BRAF V600E mutation in the absence of satisfactory locoregional treatment options.

Treatment of adults and children aged six years and older with unresectable or metastatic solid tumors with the BRAF V600E mutation who have experienced disease progression after prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Further approval for this indication may be contingent on confirmation and description of clinical benefit in confirmatory study(s).23

Treatment of children aged one year and older with BRAF V600E-mutated low-grade glioma (LGG) who require systemic therapy.23